Physician profile
Thomas A Oconnor
NPI 1992789481
$607.42
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $13.00 · 2021: $25.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $255.74 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.47 | 2019 | |
| Gilead Sciences, INC. | $119.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.33 | 2019 | |
| Novo Nordisk INC | $14.43 | 2019 | |
| Merck Sharp & Dohme LLC | $12.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.